VC-backed Synlogic and Mirna Therapeutics completes merger
Synlogic Inc and Mirna Therapeutics Inc have closed their previously announced merger. The newly combined company will operate under the Synlogic name and focus on developing medicines that treat metabolic and inflammatory diseases and cancer. Following the closing of the deal, the merged company has about $100 million in cash and cash equivalents. Also, Synlogic will start trading August 28, 2017 on the NASDAQ under the ticker symbol “SYBX." Synlogic's backers include Aju IB Investment, Ally Bridge Group, Arctic Aurora LifeScience, CLI Ventures, Perceptive Advisors, Rock Springs Capital, Atlas Venture, Deerfield, New Enterprise Associates and OrbiMed.
28 August 2017•5 mins read
